eMedicine Specialties > Emergency Medicine > Toxicology

Toxicity, Mushroom - Ibotenic Acid

Peter A Chyka, PharmD, FAACT, DABAT, Professor and Executive Associate Dean, College of Pharmacy, University of Tennessee Health Science Center
William Banner Jr, MD, PhD,, Medical Director, Oklahoma Poison Control Center; Clinical Professor of Pharmacy, Oklahoma University College of Pharmacy-Tulsa; Adjunct Clinical Professor of Pediatrics, Oklahoma State University College of Osteopathic Medicine

Updated: Oct 8, 2009

Introduction

Background

Amanita muscaria, also called fly agaric or soma, and Amanita pantherina, also called panther or panther amanita, are representative of the mushrooms in the ibotenic acid and muscimol mushroom group that produce ethanol-like intoxication and jerking movements. Symptoms typically occur within 90 minutes of ingestion, last for 4-8 hours, and resolve in most cases without drug therapy.

Fly agaric (Amanita muscaria).

Amanita pantherina.

The genus name (Amanita) and species name (muscaria) can be confusing because the names imply a type of toxin, whereas the true toxins might not be obvious. The toxin muscarine produces muscarinic pharmacologic effects (eg, salivation, bradycardia, diarrhea, miosis); this toxin was first extracted from A muscaria in 1869, but it is not a significant toxin in A muscaria. Ibotenic acid and muscimol are the major toxins in this mushroom; these substances are psychoactive, inducing a state of intoxication similar to that induced by ethanol, with a mix of excitation, sedation, and mild hallucinations. Although this mushroom is in the genus Amanita, it does not contain amatoxin, which is responsible for the serious and life-threatening nature of cyclopeptide-type mushroom poisoning.
 
Amanita muscaria is also known as fly agaric based on the olden European practice of sprinkling the mushrooms in milk as an insecticide to kill flies presumably due to the actions of ibotenic acid.

Several general types of mushrooms can cause poisoning:^1,2,3  

• Cyclopeptides (Amanita phalloides) - Hepatotoxic
• Orellanine and orelline (Cortinarius mushrooms) - Nephrotoxic
• Ibotenic acid and muscimol (A muscaria, A pantherina), also termed isoxazoles - Intoxication and jerking movements
• Gyromitrin or monomethylhydrazine (Gyromitra mushrooms) - Hemolytic
• Muscarine (Inocybe and Clitocybe mushrooms) - Cholinergic
• Coprine (Coprinus atramentarius, inky cap) - Disulfiramlike reaction
• Psilocybin (Psilocybe and Paneolus mushrooms, magic mushrooms) - Hallucinogenic
• GI irritants
• Allenic norleucine (Amanita smithiana) - Nephrotoxic

A classification of 14 syndromic categories of mushroom poisoning has been proposed, but this classification system has yet to be widely adopted.^4,5

Mushrooms in the ibotenic acid group are commonly found throughout the United States, Europe, and Asia. They are found in wooded areas, especially among conifer forests, in the spring and fall seasons of North America. The young specimens emerge with patches of membrane left covering the cap and forming a cup (volva) at the base. The mature specimens often have brilliant cap colors and delicate skirts and cups. Many everyday representations of mushrooms depict the A muscaria because of its shape and bright coloring.

Amanita muscaria.

Mushroom poisoning in children is an infrequent but perennial problem for parents and clinicians. Parental anxiety is generally high because of fears of unknown or untoward effects. Clinicians are challenged to identify such poisonings, to discern whether poisoning has taken place, to order appropriate diagnostic studies, and to prescribe reasonable therapy. The varied nature of mushroom toxicities, their ubiquitous distribution, and the relative infrequency of the ingestions make the task difficult.

Dried mushrooms have been promoted on the Internet because of their various properties, and their ingestion might lead to serious toxicity from the mushroom or from unknown adulterants added to them.⁶

Various cultures throughout the world have used fungi for ceremonies and for divinatory purposes, practices that date back 3000 years. In North America, the Algonquin people used A muscaria for religious and ritualistic ceremonies. In some European and Asian cultures, the urine of a person or a deer ingesting these mushrooms is consumed to achieve secondary intoxication.

Pathophysiology

A muscaria and A pantherina contain ibotenic acid, muscimol, and muscazone. These isoxazole derivatives are present in various concentrations depending on the environmental conditions, the maturity of the fungus, and the season of the year. Ibotenic acid and muscimol are relatively stable; for instance, toxic activity has been maintained in dried plants for as long as 7 years. Other toxins are likely present in these mushrooms because pure extracts of ibotenic acid or muscimol do not account for all of the symptoms observed after their ingestion. Ibotenic acid resembles glutamic acid, and, in animals, it acts on glutaminergic receptors to produce excitatory effects. Muscimol, formed by decarboxylation of ibotenic acid, is similar to gamma-aminobutyric acid (GABA). Both of these chemicals can cross the blood-brain barrier.⁷

Demonstrating high affinity for GABA receptors, muscimol activates GABA receptors and, thereby, can act as a sedative. Many of the CNS effects of muscimol are ascribed to its ability to act as a GABA agonist. By comparison, ibotenic acid is more of a CNS stimulant, acting on glutamic acid receptors. In humans, most of the ibotenic acid ingested is excreted unchanged in the urine. Some ibotenic acid is metabolized to muscimol. About one third of the amount of muscimol ingested is excreted unchanged, one-third is conjugated, and the rest is oxidized.⁷

Frequency

United States

In 2007, 7351 mushroom ingestions were reported to the National Poison Data System of the American Association of Poison Control Centers (AAPCC).⁸ Of these cases, 86% involved mushrooms of unknown type. Mushrooms containing ibotenic acid accounted for 43 cases, with 10 (23%) involving children younger than 6 years. About 67% of all cases involving ibotenic acid mushrooms were intentional ingestions and 77% were treated at a healthcare facility. One death was attributed to ibotenic acid mushrooms in 2004, whereas no deaths were reported in the preceding 12 years or subsequent 3 years of data collection by the AAPCC. The manner of confirming A muscaria involvement in this fatality was not described, and the fact that it was purchased on the Internet raises questions about the integrity of the contents.⁶

International

The incidence of all types of toxic mushroom poisonings, including those from the ibotenic acid group, appears to be increasing in Europe and Asia. Estimates of the actual incidence are not available.^4,5

Mortality/Morbidity

Fatalities from ibotenic acid-muscimol containing mushrooms are rare, and symptoms typically are mild to moderate in severity and self-limiting.

• From 1999-2007, 28 deaths due to mushrooms were reported to US poison control centers through the AAPCC, and one death was attributed to mushrooms containing ibotenic acid.⁶ That death in 2004 involved a 44-year-old man who ate 6-10 freeze-dried mushrooms, purported to be A muscaria, which he obtained from the Internet. Paramedics found him in cardiac arrest, and he eventually died 10 days later with anoxic brain injury. Whether the mushroom was confirmed to be A muscaria was not mentioned.
• For the 43 exposures to ibotenic mushrooms reported by US poison control centers through the AAPCC, 35% of cases had no or minor effects, 28% had moderate effects, 14% suffered severe effects, and the outcome was unknown in 23% during 2007.⁸
• Most toxic effects of mushrooms containing ibotenic acid are temporary and self-limiting, lasting 2-6 hours. Some effects, particularly headache, may take 2 days or more to resolve.^9,10
• In Slovenia, a 48-year-old man consumed several A muscaria mushrooms and, within 30 minutes, developed vomiting and lethargy.¹¹ He was found comatose, having a seizurelike episode. He awoke and was oriented 10 hours after ingestion. His condition deteriorated 18 hours after ingestion, and he became confused and uncooperative. Paranoid psychosis with visual and auditory hallucinations appeared, persisted for 5 days, and resolved with short-term drug therapy without later recurrence.
• In Poland, 5 young adults (aged 18-21 y) consumed dried A muscaria and a can of beer, and 4 of them experienced heightened visual and auditory perceptions with an onset of approximately 20 minutes. One person had severe hallucinations and a loss of consciousness according to the others. They induced vomiting and gave her liquids. The next day, she came to a hospital complaining of tiredness and gastric pain. She was evaluated, observed for several days, and sent home. No confirmation of the mushrooms was performed.¹²
• In Poland, 2 women ate 5 fried mushroom caps of Amanita pantherina (later confirmed) and developed nausea, stomachache, diarrhea, and vomiting within 2 hours. They subsequently developed ataxia, waxing and waning obtundation, altered perceptions and hyperkinetic movements, and speech. One patient's symptoms lingered for several days while the other had no symptoms at 6 hours after ingestion. The latter patient received activated charcoal and intravenous fluids.¹³
• A series of 9 children aged 1-6 years who ingested A muscaria or A pantherina were treated at a hospital in Seattle, Washington. Symptoms developed within 30-180 minutes (median, 45 min) after ingestion and lasted for 4-14 hours (median, 9 h). Typical symptoms included lethargy (4 children); unresponsiveness (1); comalike sleep (1); ataxia (2); abnormal movements (3); tonic-clonic seizures (3); and agitation, babbling, or hysteria (5). All children recovered uneventfully within 12 hours after admission.⁹
• Descriptions of cases reported to the North American Mycological Association, toxicology section, illustrate the typical course of many mushroom poisonings; however, these cases were not necessarily observed by health care professionals.¹⁴

Age

Adults are frequently involved as foragers for edible mushrooms. Because of errors in identification, they may ingest toxin-containing look-alike mushrooms. Adults and adolescents may also be poisoned when they intentionally consume mushrooms, picked from the ground or purchased dried, to achieve intoxication. Young children may be poisoned by mushrooms when they unintentionally eat mushrooms found outside, typically in yards or outdoor play areas. Reports of seizurelike activity have been reported for children but are not typical in adults.^9,10

Clinical

History

Ask the patient about how many mushrooms were consumed, how they were prepared, and when the mushrooms were eaten. The concentration of active substances is low in any one mushroom, but generally about 1 mushroom in young children and 3 or more in adolescents and adults produce toxic symptoms.¹⁰ The effects of mushrooms vary greatly, and cooking may not alter toxicity. An amount as small as a mouthful can cause symptoms.⁹

• Obtain a history of the exposure that includes the following:
  • Quantity of mushrooms ingested
    • Preparation of the mushroom (eg, raw, cooked)
    • Source of the mushroom (eg, outdoors, the Internet)
    • Time of the ingestion
    • Symptoms and time of onset after ingestion
    • Prehospital treatment including home remedies
    • Medications regularly taken and any coingestants
• The timing of symptom onset is a crucial element of the history in differentiating life-threatening or severe mushroom poisonings from those that are less serious and typically have an onset of symptoms well within 5 hours of ingestion such as the mushrooms of the ibotenic acid group.^4,5,1,2,3
  • Mushrooms from the cyclopeptide (Amanita phalloides) or orellanine (Cortinarius mushrooms) groups that can produce hepatic or renal failure, respectively, typically produce symptoms 6-24 h after ingestion.
  • Amanita smithiana (allenic norleucine group) found in the Northwestern states can also be nephrotoxic, but it has an onset of gastrointestinal distress within 1-12 hours.¹⁵ These mushrooms are often confused with edible pine mushrooms.
  • For mushroom ingestions in the Pacific Northwest region of the United States, patients who have early-onset symptoms and remain symptomatic should be fully evaluated in a hospital until the mushroom identity is confirmed to be nontoxic or the patient’s condition improves.³
• Identification of the actual mushroom consumed is important but is typically impossible because the mushroom in question has already been digested.
  • A muscaria has a scarlet cap, is 5-30 cm in diameter and contains white warts. The stalk is white, is frequently hollow, and is often as long as 15-20 cm. A prominent cup (volva) is found at the bottom of the stalk, with numerous rings superiorly. The gills of A muscaria are free and white. The spores are also white. Its appearance can vary depending on the geographic location. The scarlet cap is predominantly found in western North America. Caps that are orange to yellow-orange caps are most frequent in eastern North America.
  • A muscaria can occur alone or in groups on the ground of forests, in grassy areas and lawns, and especially under trees.
  • Different types of mushrooms can be found in the same location, and a single sample can lead to false identification of the mushroom that was ingested. Consider all possible mushrooms in the immediate vicinity of where the ingestion occurred.
  • When no specimen is brought in by a patient with a suspected mushroom ingestion, sending an experienced forager to the site to collect any mushrooms growing in the area might be helpful.
  • When mushrooms are obtained for identification, the entire mushroom should be dug up to preserve the architecture of the bulb, stem, and cap. Place individual mushrooms in a dry paper bag, not a plastic or cloth bag. Transporting the mushrooms in a careful, dry manner minimizes destruction of the natural architecture of the mushrooms, discoloration of the cap or gills, and premature release of the spores. Do not refrigerate or crush the mushrooms.
  • Collecting the patient's gastric contents by means of gastric lavage or after emesis might yield identifiable spores.
  • Remote viewing of the mushroom by digital photography and Internet transmission may aid the identification of unknown mushrooms by mycologists.¹⁶

Physical

Once ingested, A muscaria produces symptoms within 30-90 minutes. Peak effects occur at 2-3 hours. The initial symptom is drowsiness, followed by confusion, ataxia, dizziness, euphoria, and intoxication. These symptoms can proceed to hyperkinesis, muscle jerks, spasms, and delirium. Deep sleep or coma can occur and generally lasts 4-8 hours.

• If symptoms such as vomiting, diarrhea, and abdominal pain begin 5 hours or more after ingestion, poisoning with the potentially life-threatening or severe mushrooms such as the cyclopeptide (Amanita phalloides) or orellanine (Cortinarius mushrooms) groups, which can produce hepatic or renal failure, respectively, should be considered.^4,5,1,2,3  Amanita smithiana (allenic norleucine group) found in the Northwestern United States can also be nephrotoxic, but it has an onset of gastrointestinal distress within 1-12 hours after ingestion.¹⁵ For mushroom ingestions in the Pacific Northwest region of the United States, patients who have early-onset symptoms and remain symptomatic should be fully evaluated in a hospital until the mushroom identity is confirmed or the patient's condition improves.³
• Vital signs: Pulse and blood pressure are usually unchanged.
• Respiration: Breathing is slow and regular, similar to that in deep sleep.
• GI: GI upset and vomiting occur but are not common. When vomiting or diarrhea does occur, fluid and electrolyte changes are uncommon.
• Integumentary: Skin may be reddened and warm to the touch.
• Musculoskeletal: Muscle spasms may occur.
• Neurologic: Agitation and CNS depression may occur. 
  • Especially in children, tonic-clonic seizures, fasciculations, and myoclonic jerking lasting 6-9 hours have been reported.⁹ Seizures in adults are uncommon.
  • Initial excitation leads to stupor, then coma; severe lethargy alternating with agitation is common, and a deep sleep may occur.
  • Agitation, babbling, confusion, screaming, irritability, hallucinations, dizziness, ataxia, euphoria progressing to muscle jerks, spasms, delirium, racing thoughts, and giddiness may be seen.
  • Headache may last several days.
  • Illusions of sight and sound are produced by misinterpretation of sensory input.

Causes

• Incorrect mushroom identification by a naive forager such as an immigrant who mistakes one of the local poisonous varieties for an edible mushroom native to his or her homeland or a novice mushroom harvester
• Intentional ingestion by a suicidal person
• Unintentional ingestion by a child who found mushrooms growing in yards or outdoor play areas
• Foul play in which an individual is poisoned by someone else
• Inadvertent poisoning from dried mushrooms purchased on the Internet or from other sources where the composition of the mushroom is unreliable or where the mushroom might contaminated with unknown toxic compounds

Differential Diagnoses

Toxicity, Ethanol
Toxicity, Hallucinogens - LSD
Toxicity, Hallucinogens - PCP

Other Problems to Be Considered

Ingestions

Psilocybe species
Amanita cothurnata
Amanita smithiana
Amanita strobiliformis
Amanita gemmata

When other members of the Amanita genus are suspected

Ketamine toxicity
Meningoencephalitis
Dextromethorphan toxicity
g Hydroxybutyrate toxicity

Workup

Laboratory Studies

• Several texts, such as Goldfrank's Toxicological Emergencies,³   describe how to determine if the suspect botanical contains amatoxin, a potent toxin found in some of the Amanita species. However, for symptomatic patients, identification of the mushroom by a mycologist is desirable. (See Consultations.)
• Obtain a complete blood count because some mushroom toxins (eg, gyromitrin) can cause hemolytic anemia.
• Baseline liver function studies are indicated because possible ingestion of other toxic mushrooms, such as cyclopeptide-type mushrooms, can cause hepatotoxicity.
• Baseline renal function studies are indicated because some mushrooms are nephrotoxic, such as Amanita smithiana ( in Northwestern US) and orelline mushrooms.
• Consider evaluation for rhabdomyolysis if signs and symptoms warrant because some mushrooms, Tricholoma equestre, may cause muscle toxicity.
• Obtain a basic serum metabolic profile (sodium, potassium, chlorine, carbon dioxide, creatinine, glucose, and calcium) to evaluate for fluid and electrolyte disturbances due to other offending ingestants.
• Urine drug screening should be considered, especially if the patient has unexplained symptoms or behavioral changes, if suicidal intent, substance abuse or foul play is suspected, or if ingestion of unknown toxins is suspected.
• The patient's urine may be analyzed for muscimol to confirm muscimol poisoning, but this test is not typically available in hospital laboratories.
• Chromatographic techniques (eg, thin-layer chromatography [TLC], gas-liquid chromatography [GLC], high-pressure liquid chromatography [HPLC]) are available to detect amanitins, orellanine, muscimol and ibotenic acid, psilocybin, muscarine, and the gyromitrins. However, these techniques are typically unavailable to the general practitioner because they are limited to laboratories conducting research on these compounds.

Imaging Studies

• If the diagnosis is uncertain, and if blunt head trauma is part of the differential diagnosis because of changes in mental status, obtain a plain CT scan of the head before lumbar puncture is performed.

Other Tests

• Gastric contents may be examined. A mycologist may be able to microscopically identify the spores recovered from the patient's gastric contents.

Procedures

• No particular diagnostic procedures are available or needed for most patients with toxicity from mushrooms containing muscimol or ibotenic acid.

Treatment

Medical Care

• Symptomatic patients may be treated with supportive measures.
• The entire episode usually subsides in 6-8 hours; some symptoms may take up to several days to fully resolve.
• Patients with severe agitation or seizures may require benzodiazepines. Be aware that respiratory depression has been reported when these agents are administered intravenously (IV). Be prepared to support the airway if needed.¹⁰

Consultations

• Consult a mycologist to assist with mushroom identification. A mycologist can be contacted through the local poison center (in the United States, call 800-222-1222), a mycology club, the North American Mycological Association, a botanical garden, or local university.
• Consultation with a medical toxicologist may be helpful, if available.
• Consult a psychiatrist when the patient may have had suicidal intent.

Medication

Most patients with poisoning due to ibotenic acid mushrooms can be treated without medications. If patients are severely agitated, anxiolytics may be needed. For seizures lasting longer than 5 minutes, various anticonvulsants have been used. If the patient presents within 1 hour of ingestion, oral administration of activated charcoal may be considered,¹⁷ but adsorption to activated charcoal has not been demonstrated for these constituents.¹⁸ No evidence suggests that routine administration of multiple doses of activated charcoal is useful.

Ipecac syrup should generally be avoided because of the relatively rapid onset of CNS symptoms after ingestion of ibotenic acid mushrooms and evidence for its effectiveness is lacking. Although these mushrooms are named A muscaria, few muscarinic effects are observed and anticholinergic drugs such as atropine are rarely, if ever, needed.

Benzodiazepine

Benzodiazepines are first-line agents for controlling seizures in patients with toxicity. They are also helpful in sedating patients with extreme agitation.

Diazepam (Valium)

Useful for agitation or seizures. Depresses all levels of CNS (eg, limbic and reticular formation), possibly by increasing activity of GABA.

Dosing

Adult

2.5-10 mg PO/IV/IM, may repeat every 5-10 min

Pediatric

0.05-0.1 mg/kg/dose PO/IV/IM

Interactions

Increase CNS toxicity with coadministration of other CNS depressants (eg, phenothiazines, barbiturates, alcohols, monoamine oxidase inhibitors [MAOIs]); cytochrome P450 (CYP) 1A2 and CYP2C19 substrate, coadministration of isoenzyme 1A2 and 2C19 inhibitors (eg, cimetidine, fluconazole, erythromycin) may decrease clearance

Contraindications

Documented hypersensitivity; narrow-angle glaucoma

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Respiratory depression, acute narrow-angle glaucoma may be precipitated, use with caution with impaired renal or hepatic function; may cause cardiovascular collapse, blood dyscrasias, hypotension, drowsiness, fatigue, ataxia, or confusion

Lorazepam (Ativan)

Useful for agitation or seizures. By increasing action of GABA (major inhibitory neurotransmitter in brain), may depress all levels of CNS, including limbic and reticular formation.

Dosing

Adult

2-4 mg PO/IV/IM, administer 4 mg initially, may repeat in 10-15 min

Pediatric

0.05-0.1 mg/kg PO/IV/IM; not to exceed 2 mg/dose

Interactions

CNS toxicity increases when used concurrently with alcohol, phenothiazines, barbiturates, or MAOIs

Contraindications

Documented hypersensitivity; preexisting CNS depression, hypotension, and narrow-angle glaucoma

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Acute narrow-angle glaucoma, caution with impaired renal or hepatic function; may cause cardiovascular collapse, respiratory depression, blood dyscrasias, hypotension, drowsiness, fatigue, ataxia, or confusion

Midazolam (Versed)

Used as alternative in termination of refractory status epilepticus. Because midazolam is water soluble, it takes approximately 3 times longer than diazepam to achieve peak EEG effects; wait 2-3 min to fully evaluate sedative effects before initiating procedure or repeating dose.

Dosing

Adult

Loading: 0.2 mg/kg IV
Maintenance: 0.1-0.4 mg/kg/h continuous IV infusion
Alternatively: 10-15 mg IM; when other access impossible

Pediatric

Loading: 0.15 mg/kg IV
Maintenance dose: 1 mcg/kg/min continuous IV infusion
Titrate maintenance dose upward q5min until clinical seizure activity is controlled

Interactions

Sedative effects of midazolam may be antagonized by theophyllines; narcotics and erythromycin may accentuate sedative effects of midazolam due to decreased clearance

Contraindications

Documented hypersensitivity; preexisting hypotension, narrow angle glaucoma

Precautions

Pregnancy

D - Fetal risk shown in humans; use only if benefits outweigh risk to fetus

Precautions

Intubation and pressor support necessary for continuous IV infusion; caution in congestive heart failure, pulmonary disease, renal impairment, and hepatic failure

Follow-up

Further Inpatient Care

• Administer IV fluids if vomiting becomes prominent, although this is rare.
• Provide psychiatric care to patients with intentional ingestions and suicidal thinking.

Deterrence/Prevention

• Avoid eating mushrooms that are not commercially cultivated for human consumption.
• Cautious mushroom hunters eat only one type of mushroom and save a sample in a dry paper bag for later identification, if needed.
  • Identification of mushrooms is best left to experts.
  • Prevention is best achieved by eating only commercially cultivated mushrooms.
  • Regularly remove mushrooms from sites where children are routinely present.

Prognosis

• The prognosis is excellent because many patients who ingest these mushrooms only exhibit minor or no symptoms. Symptoms are typically self-limited, and patients recover without drug therapy.

Multimedia

Media file 1: Fly agaric (Amanita muscaria).

Media file 2: Amanita pantherina.

Media file 3: Amanita muscaria.

Media file 4: Amanita muscaria var. guessowii with a yellow cap surface, Massachusetts.

Media file 5: Amanita muscaria var. formosa sensu, Thiers, Oregon.

References

1. Berger KJ, Guss DA. Mycotoxins revisited: Part I. J Emerg Med. Jan 2005;28(1):53-62. [Medline].

2. Berger KJ, Guss DA. Mycotoxins revisited: Part II. J Emerg Med. 2005b Feb;28(2):175-83. [Medline].

3. Goldfrank LR. Mushrooms. In: Flomenbaum NE, Goldfrank LR, Hoffman RS, Howland MA, Lewin NA, Nelson LS. Goldfrank's Toxicologic Emergencies. 8^th ed. New York: McGraw-Hill; 2006:1564-76.

4. Diaz JH. Evolving global epidemiology, syndromic classification, general management, and prevention of unknown mushroom poisonings. Crit Care Med. Feb 2005;33(2):419-26. [Medline].

5. Diaz JH. Syndromic diagnosis and management of confirmed mushroom poisonings. Crit Care Med. Feb 2005;33(2):427-36. [Medline].

6. Watson WA, Litovitz TL, Rodgers GC Jr, et al. 2004 Annual report of the American Association of Poison Control Centers Toxic Exposure Surveillance System. Am J Emerg Med. Sep 2005;23(5):589-666. [Medline].

7. Michelot D, Melendez-Howell LM. Amanita muscaria: chemistry, biology, toxicology, and ethnomycology. Mycol Res. Feb 2003;107(Pt 2):131-46. [Medline].

8. Bronstein AC, Spyker DA, Cantilena LR Jr, Green JL, Rumack BH, Heard SE. 2007 Annual Report of the American Association of Poison Control Centers' National Poison Data System (NPDS): 25th Annual Report. Clin Toxicol (Phila). Dec 2008;46(10):927-1057. [Medline].

9. Benjamin DR. Mushroom poisoning in infants and children: the Amanita pantherina/muscaria group. J Toxicol Clin Toxicol. 1992;30(1):13-22. [Medline].

10. Poisindex managements, mushrooms – muscimol / ibotenic acid. In: Poisindex System [Internet database online] [database online]. Greenwood Village (CO): Thomson Reuters (Healthcare); February 27, 2009.

11. Brvar M, Mozina M, Bunc M. Prolonged psychosis after Amanita muscaria ingestion. Wien Klin Wochenschr. May 2006;118(9-10):294-7. [Medline].

12. Satora L, Pach D, Butryn B, Hydzik P, Balicka-Slusarczyk B. Fly agaric (Amanita muscaria) poisoning, case report and review. Toxicon. Jun 1 2005;45(7):941-3. [Medline].

13. Satora L, Pach D, Ciszowski K, Winnik L. Panther cap Amanita pantherina poisoning case report and review. Toxicon. Apr 2006;47(5):605-7. [Medline].

14. NAMA (North American Mycological Association). Annual reports. North American Mycological Association, Toxicology Section. Available at http://www.namyco.org/toxicology. Accessed March 4, 2009.

15. West PL, Lindgren J, Horowitz BZ. Amanita smithiana mushroom ingestion: a case of delayed renal failure and literature review. J Med Toxicol. Mar 2009;5(1):32-8. [Medline].

16. Fischbein CB, Mueller GM, Leacock PR, Wahl MS, Aks SE. Digital imaging: a promising tool for mushroom identification. Acad Emerg Med. Jul 2003;10(7):808-11. [Medline].

17. Beuhler MC, Sasser HC, Watson WA. The outcome of North American pediatric unintentional mushroom ingestions with various decontamination treatments: an analysis of 14 years of TESS data. Toxicon. Mar 15 2009;53(4):437-43. [Medline].

18. Chyka PA, Seger D, Krenzelok EP, Vale JA. Position paper: Single-dose activated charcoal. Clin Toxicol (Phila). 2005;43(2):61-87. [Medline]. [Full Text].

Keywords

ibotenic acid, fly agaric mushroom, ibotenic acid mushrooms, muscimol, panther mushroom, mushroom poisoning, mushroom poisoning symptoms

Contributor Information and Disclosures

Author

Peter A Chyka, PharmD, FAACT, DABAT, Professor and Executive Associate Dean, College of Pharmacy, University of Tennessee Health Science Center
Peter A Chyka, PharmD, FAACT, DABAT is a member of the following medical societies: American Academy of Clinical Toxicology, American College of Clinical Pharmacy, and American Society of Health-System Pharmacists
Disclosure: Nothing to disclose.

Coauthor(s)

William Banner Jr, MD, PhD,, Medical Director, Oklahoma Poison Control Center; Clinical Professor of Pharmacy, Oklahoma University College of Pharmacy-Tulsa; Adjunct Clinical Professor of Pediatrics, Oklahoma State University College of Osteopathic Medicine
William Banner Jr, MD, PhD, is a member of the following medical societies: American College of Medical Toxicology
Disclosure: Nothing to disclose.

Medical Editor

Michael E Mullins, MD, Assistant Professor, Department of Emergency Medicine, Washington University School of Medicine
Michael E Mullins, MD is a member of the following medical societies: American Academy of Clinical Toxicology and American College of Emergency Physicians
Disclosure: Johnson & Johnson stock ownership None; Savient Pharmaceuticals stock ownership None

Pharmacy Editor

Mary L Windle, PharmD, Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy, Pharmacy Editor, eMedicine
Disclosure: Pfizer Inc Stock Investment from financial planner; Avanir Pharma Stock Investment from financial planner ; WebMD Salary and stock Employment and investment from financial planner

Managing Editor

Jeffrey R Tucker, MD, Assistant Professor, Department of Pediatrics, Division of Emergency Medicine, University of Connecticut and Connecticut Children's Medical Center
Jeffrey R Tucker, MD is a member of the following medical societies: American Academy of Clinical Toxicology, American Academy of Pediatrics, and Massachusetts Medical Society
Disclosure: Merck Salary Employment

CME Editor

Daniel Rauch, MD, FAAP, Director, Pediatric Hospitalist Program, Associate Professor, Department of Pediatrics, New York University School of Medicine
Daniel Rauch, MD, FAAP is a member of the following medical societies: Ambulatory Pediatric Association, American Academy of Pediatrics, and Society of Hospital Medicine
Disclosure: Baxter Honoraria Consulting

Chief Editor

Timothy E Corden, MD, Associate Professor of Pediatrics, Co-Director, Policy Core, Injury Research Center, Medical College of Wisconsin; Associate Director, PICU, Children's Hospital of Wisconsin
Timothy E Corden, MD is a member of the following medical societies: American Academy of Pediatrics, Phi Beta Kappa, Society of Critical Care Medicine, and Wisconsin Medical Society
Disclosure: Nothing to disclose.

The authors and editors of eMedicine gratefully acknowledge the contributions of previous author, Martin I Herman, MD, to the development and writing of this article

© 1994- by Medscape.
All Rights Reserved
(http://www.medscape.com/public/copyright)